Aktienanalyse zu Nyxoah SA (NYXH)

KI-Analyse of Nyxoah SA (NYXH)

Halten

Nyxoah SA (NYXH) is currently not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $0.88, significantly down from its 52-week high of $5.92, reflecting an 80.44% year-to-date decline. Although the company reported a 21% revenue growth in Q2 2026, its forward P/E is at 0, indicating no earnings growth expected in the near term. The RSI is at 30.874, suggesting it is oversold, but the overall sentiment remains cautious due to recent downgrades from analysts, with Cantor Fitzgerald lowering its price target to $3 from $6. The main risk is the company's ongoing net losses, which reached €32.96 million in Q2 2026, indicating financial instability. Therefore, while there are some positive indicators, the risks outweigh the potential for immediate gains, making it prudent to hold rather than buy at this time.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Nyxoah SA (NYXH) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -4.19.

Erwartetes KGV

Überbewertet

5J-Durchschnitt P/E

-4.19

Aktuelles P/E

0.00

Überbewertet

-0.85

Unterbewertet

-7.52

Erwartetes EV/EBITDA

Fair bewertet

5J-Durchschnitt EV/EBITDA

-3.12

Aktuelles EV/EBITDA

-0.42

Überbewertet

-0.25

Unterbewertet

-5.99

Erwartetes KUV

Fair bewertet

5J-Durchschnitt P/S

23.23

Aktuelles P/S

1.26

Überbewertet

45.85

Unterbewertet

0.61

Alphio-AI-Kursszenarien für NYXH

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%NYXH

$9.24

Szenariopreis

B

Basis

Basis · 50%NYXH

$7.86

Szenariopreis

B

Bärisch

Bärisch · 25%NYXH

$7.48

Szenariopreis

Whales, die NYXH halten

P

Pentwater Capital Management LP

+ HältNYXH

-3.88%

3-Monats-Rendite

NYXH FAQ – beantwortet von Alphio AI

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin. It operates in the Healthcare sector.

Nyxoah SA (NYXH) is currently not a strong buy due to its recent performance and analyst downgrades. The stock is trading at $0.88, significantly down from its 52-week high of $5.92, reflecting an 80.44% year-to-date decline. Although the company reported a 21% revenue growth in Q2 2026, its forward P/E is at 0, indicating no earnings growth expected in the near term. The RSI is at 30.874, suggesting it is oversold, but the overall sentiment remains cautious due to recent downgrades from analysts, with Cantor Fitzgerald lowering its price target to $3 from $6. The main risk is the company's ongoing net losses, which reached €32.96 million in Q2 2026, indicating financial instability. Therefore, while there are some positive indicators, the risks outweigh the potential for immediate gains, making it prudent to hold rather than buy at this time.